Eli Lilly's highly anticipated obesity pill yields modest results.
Lilly's new oral GLP-1, orforglipron, shows 11-12.4% weight loss in late-stage trial, short of Zepbound and Wegovy. Easier to produce and distribute than injectables, it targets wider patient access. FDA submission this year.
